AHR and microcephaly: Most importantly, an AHR antagonist optimized for human use boosted antiviral immunity, interfered with viral replication and ameliorated multiple aspects of Zika congenital syndrome including microcephaly in animal models18, identifying AHR as a candidate target for therapeutic intervention.